喹硫平联合氟哌啶醇对精神分裂症患者激越行为的影响

Effects of quetiapine combined with haloperidol on the aggressive behavior of schizophrenic patients

目的探讨喹硫平联合氟哌啶醇治疗对精神分裂症患者激越行为的影响。方法采用回顾性研究方法,2015年1月—2016年9月选择在新乡医学院第二附属医院诊治的精神分裂症患者115例,根据治疗方法的不同分为观察组60例与对照组55例,对照组给予喹硫平治疗,观察组给予喹硫平联合氟哌啶醇治疗,比较两组的治疗效果、不良反应、血脂改变及激越行为评分情况。结果观察组的总有效率96.7%(58/60)高于对照组87.3%(48/55),差异有统计学意义(P<0.05)。观察组的不良反应发生率为21.7%(13/60),对照组为21.8%(12/55),且两组的不良反应都为轻中度。治疗后两组血清低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)含量对比无差异。治疗后观察组与对照组的激越行为评分分别为(8.14±6.33)分和(13.01±6.10)分,显著低于治疗前的(22.22±5.33)分和(22.09±4.82)分(P<0.05),同组治疗前后比较差异有统计学意义(P<0.05);且观察组明显低于对照组,差异有统计学意义(P<0.05)。结论喹硫平联合氟哌啶醇治疗精神分裂症患者能有效控制激越行为,提高治疗效果,且不会增加不良反应的发生,也不会影响患者的血脂水平,有很好的应用价值。

Objective To investigate the effects of quetiapine combined with haloperidol on the aggressive behavior of schizophrenic patients. Methods Used a retrospective study, From January 2015 to September 2016, 115 patients with aggressive behavior of schizophrenic patients in our hospital for treatment were selected. All the patients were divided into the observation group of 70 patients and control group of 45 patients accorded to the different methods of drugs, the control group was treated with quetiapinet, the observation group was quetiapine combined with haloperidol. Compare the therapeutic effect of two groups. Results The total effective rate of observation group was 96.7%（58/60） compared to 87.3%（48/55） of the control group（P 〈 0.05）. The adverse reaction rate of the observation group was 21.7%（13/60）, and the control group was 21.8%（12/55）, and the adverse reactions in both groups were mild to moderate. After treatment, the content of serum HDL-C, TC and TG in the observation group werelower than that of the control group（P 〈 0.05）, and there were no difference in the comparison of the content of HDL-C in the two groups. After treatment, the agitation score of the observation group and the control group were（8.14 ± 6.33） points and（13.01 ± 6.10） points, which was significantly lower than those before treatment of（22.22 ± 5.33） points and（22.09 ± 4.82） points（P 〈 0.05）. The observation group was lower than the control group（P 〈 0.05）. Conclusion The quetiapine combined with haloperidol in the treatment of schizophrenia can effectively control the agitation behavior, improve the treatment effect, and will not increase the occurrence of adverse reactions, and will not affect the level of blood lipids of patients. It has a very good application value.